Exicure, Inc. (Nasdaq: XCUR) today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. Exicure, Inc. ("Exicure") is planning for a clinical trial in Acute Myeloid ...

A Winnipeg couple has temporarily relocated to Memphis, Tennessee, in search of lifesaving treatment for their 3-year-old son ...

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ ...

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

About 6% of pregnancy-related cancers are Hodgkin lymphoma, and 5% are non-Hodgkin lymphoma. Leukemias in pregnancy are rarer ...

Ziftomenib’s FDA application for relapsed/refractory NPM1-mutant acute myeloid leukemia is supported by data from the ...

SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.

Ziftomenib has received Breakthrough Therapy, Fast Track, and Orphan Drug Designations. The FDA has a 60-day filing review period to determine whether the NDA is complete and accepted for review; Kura ...

Syndax has a strong cash position and a significant market opportunity with Revuforj and Niktimvo. Check out my ...